Onciummune CEO, Dr Adam Hill, discusses the Company’s latest contract wins with Roche and Cedars-Sinai along with the use of funds from their recent oversubscribed fundraise and what investors can expect for the remainder of 2021.
Onciummune CEO, Dr Adam Hill, discusses the Company’s latest contract wins with Roche and Cedars-Sinai along with the use of funds from their recent oversubscribed fundraise and what investors can expect for the remainder of 2021.